ReviewOncology reports2026
Targeting colorectal cancer and T‑cell metabolism for the treatment of colorectal cancer (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a malignant tumor of the digestive tract that is highly prevalent worldwide, which is associated with a poor prognosis in advanced stages and for which current treatment plans have limited efficacy. T cells serve a crucial role in immune clearance and immune evasion within the tumor microenvironment. However, tumor cells directly impair the function of T cells through nutrient competition and the release of inhibitory metabolites. Notably, targeting 'metabolic checkpoints' has emerged as a crucial strategy to enhance T‑cell efficacy. The present literature review summarizes the role of reprogramming glycolysis, glutaminolysis and lipid metabolism in driving immune evasion in CRC, and discusses potential intervention strategies from two perspectives: Modulating tumor metabolism and optimizing the intrinsic metabolic functions of T cells. Finally, it is proposed that stratified precision therapy based on individual metabolic profiles represents a future direction for overcoming immune heterogeneity and drug resistance in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.